You are here: Industry Insights > Orelabrutinib

News List

Orelabrutinib: A Novel BTK inhibitor David Orchard-Webb
March 01, 2024
Orelabrutinib, developed by InnoCare Pharma, is an orally bioavailable, second-generation Bruton's tyrosine kinase (BTK) inhibitor.
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China PharmaSources
April 27, 2025
InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum PharmaSources
February 26, 2025
InnoCare Pharma Announced today that the Phase II Results of Orelabrutinib for the Treatment of Relapsing-Remitting Multiple scler.
Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024 PharmaSources
September 14, 2024
Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology PharmaSources
April 18, 2024
The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.
InnoCare Releases 2023 Results and Business Highlights PharmaSources
March 29, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023 PharmaSources
December 14, 2023
?InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.